# Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
Canonical URL: https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-to-present-at-td-cowen-s-7th-annual-oncology-innovation-summit
Ticker: ACRV
Company: Acrivon Therapeutics
Source: Acrivon Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.acrivon.com
## Summary

WATERTOWN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive

## Article Body
WATERTOWN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive
## Recent Company News
- 2026-06-25 13:46 EST — [Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit](https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-to-present-at-td-cowen-s-7th-annual-oncology-innovation-summit) — Source: Acrivon Therapeutics
- 2026-06-25 13:46 EST — [Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts](https://biopharmsignal.com/news/ACRV/acrivon-reports-first-quarter-2026-financial-results-and-highlights-progress-towards-key-2026-clinical-catalysts) — Source: Acrivon Therapeutics
- 2026-06-25 13:46 EST — [Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast](https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-to-announce-clinical-update-on-its-ongoing-phase-2b-studies-and-planned-confirmatory-phase-3-trial-for-acr-368-initial-clinical-data-on-acr-2316-and-other-ap3-pipeline-updates-via-webcast) — Source: Acrivon Therapeutics
- 2026-06-25 13:46 EST — [Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11](https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-announces-positive-acr-368-phase-2b-endometrial-cancer-clinical-data-with-eu-expansion-to-accelerate-enrollment-initial-acr-2316-clinical-data-and-acr-6840-its-next-ap3-enabled-development-candidate-targeting-cdk11) — Source: Acrivon Therapeutics
- 2026-06-25 13:46 EST — [Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress](https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-announces-late-breaking-oral-presentation-at-upcoming-european-society-of-gynecological-oncology-esgo-annual-international-congress) — Source: Acrivon Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)